


PHARMACEUTICAL 2017

Regen BioPharma Inc Rank 289 of 292







Regen BioPharma Inc Rank 289 of 292

The relative strengths and weaknesses of Regen BioPharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Regen BioPharma Inc compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 98% points. The greatest weakness of Regen BioPharma Inc is the variable Assets, Current, reducing the Economic Capital Ratio by 1,207% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,429%, being 1,432% points below the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	207
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	799
Liabilities, Non-Current	0
Other Assets	112
Other Compr. Net Income	0
Other Expenses	722
Other Liabilities	107
Other Net Income	-4,794
Other Revenues	100
Property and Equipment	0
Research and Development	671
Selling, General and Administrative Expense	1,664

Output Variable	Value in 1000 USD
Assets	319
Liabilities	906
Expenses	3,057
Revenues	100
Stockholders Equity	-587
Net Income	-7,751
Comprehensive Net Income	-7,751
Economic Capital Ratio	-1,429%

